Press Release


					
Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points

					

					


					

						

							

								
    

  • Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo 
    • 

  • Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® 
    • 

  • Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors
    • 



Ona Therapeutics (“Ona”), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced the appointment of Dr. Antoine Yver, M.D., M.Sc., as Chair of its Board of Directors. This strategic appointment marks a defining step in the Company’s growth as it prepares to advance its lead ADC, ONA-255, into clinical trials for breast cancer treatment in early 2026.


With over 35 years of leadership in global oncology drug development, Dr. Antoine Yver has held senior executive roles at industry leaders including Daiichi Sankyo, AstraZeneca, Johnson & Johnson, and Merck. He has played a key role in advancing and securing regulatory approvals for 13 landmark cancer therapies, including breakthrough medicines such as ENHERTU, TAGRISSO, and LYNPARZA, all of which have transformed standards of care for patients worldwide.


At Daiichi Sankyo, Dr. Yver served as Global Head of Oncology R&D, and at AstraZeneca, he led the oncology development programs. His leadership in bringing ENHERTU, a pioneering ADC for breast cancer, from initial first-in-human clinical studies to global approval, exemplifies his deep expertise and will be invaluable to Ona as it advances its innovative ADC pipeline toward clinical development.


Valerie Vanhooren, Ph.D., Co-Founder and Chief Executive Officer at Ona Therapeutics, said: “Antoine’s unparalleled experience in advancing first-in-class oncology drugs at lightning speed from translational research through global approval will be critical as we advance our lead candidate, ONA-255, into clinical development in breast cancer. Equally important is our commitment to progressing our second ADC, ONA-389, targeting microsatellite stable (MSS) colorectal cancer and hepatocellular carcinoma, both high-unmet-need indications with significant market potential. Antoine’s patient-centric vision aligns perfectly with Ona’s mission to deliver transformative ADC therapies, and his strategic guidance will be invaluable as we accelerate growth and value creation in this next phase.” 


Dr. Yver is currently an Independent Director on the Board of Sanofi, where he contributes strategic and scientific insight at the governance level. He also serves on the boards of several oncology-focused companies, as well as the scientific advisory committee for Gustave Roussy Cancer Institute, further demonstrating his broad scientific and business influence and commitment to advancing cancer therapies.


Ona’s proprietary patient-based discovery platform uniquely unlocks new biological targets that are not exploited by current ADCs or standard therapies, giving the Company a significant competitive edge. Its lead candidate, ONA-255, targets a unique first-in-class mechanism and is perfectly suited for the treatment of advanced cancers, particularly breast cancer. This candidate is advancing toward clinical trials in early 2026 and is also demonstrating broad potential across breast, gastric, and other solid tumors. Its second candidate, ONA-389, is focused on high-unmet-need indications such as MSS colorectal cancer and hepatocellular carcinoma. Together, these programs underscore Ona’s innovative approach to developing transformative therapies for difficult-to-treat solid tumors.


Dr. Antoine Yver, M.D., M.Sc., newly appointed Chair of the Board of Ona Therapeutics, added: “Breast cancer remains the most prevalent cancer among women worldwide. Having witnessed firsthand the transformative impact ADCs can have for the treatment paradigm of breast cancer and the direct clinical benefit for patients, I recognize the compelling potential of Ona’s approach in identifying novel tumor targets in breast cancer and other major solid tumors. I’m thrilled to join the Company at this pivotal stage to help ensure clinical readiness, guide swift, focused, and effective development strategy, and support the team in executing and advancing its pipeline and bringing next-generation ADCs to the patients who need them most.” 


							

						

					

				

			

		

	

			

					


					
			
	
	
	
	


















    
	
	
	
	

		    
		
				

		


	Ona Therapeutics



		
    
			

  • 
	

    • 

	
  • 
	
	
    • 


	
  • 
	
	
    • 



	
  • 
	
	
    • 
		

		


			Powered by ONA THERAPEUTICS, SL  GDPR Cookie Compliance
		


		

		
		

		

			 
		

		
		


			

			


		Privacy Overview
		

	
ONA THERAPEUTICS, SL obtains personal data through the contact forms of the web, from those who submit any questions, requests and / or comments.


In accordance with current regulations on Data Protection, specifically, Regulation (EU) 2016/679 of the European Parliament and of the Council, of April 27, 2016, personal data provided to ONA THERAPEUTICS, SL through this web portal will become part of its information systems that comply with the security measures required in order to guarantee the confidentiality, integrity, security and information retrieval.


The purposes for which these data are collected are those of being able to respond to your queries regarding the services we offer. In addition, of the timely response to your queries, we may, if you authorize us to do so, send you information electronically.


Your data will be kept for the period that you are registered to receive the requested information, being your revocable consent, it may be withdrawn at any time through the link that accompanies each shipment to communicate your WITHDRAWN or through an email to the address info@ona-therapeutics.com. From that moment, you will no longer receive any communication from us.


We will not proceed with the communication or transfer of your data, in any case, unless a public body requires it in accordance with the Law and those in charge of treatment that provide services related to our information systems.


You have the right to obtain confirmation about whether we are treating your personal data, therefore, you have the right to access your personal data (Right of Access), you have the right to rectify inaccurate data (Right of Rectification) or to request its deletion (Right to deletion) when the data is no longer necessary, you have the right to exercise your opposition to the processing of data (Right of opposition), to exercise your right to the limitation of the processing, as well as you will have the right to the portability of your data, if it is the case. All this by writing to our access addresses in Calle Baldiri Reixach 10, Barcelona, ​​Spain or via email info@ona-therapeutics.com in accordance with the procedure of articles 15 to 23 of Regulation (EU) 2016 / 679 of the European Parliament and of the Council, of April 27, 2016.


ONA THERAPEUTICS, SL, declares to have implemented the necessary technical and organizational security measures that guarantee the security of the data and prevent its alteration, loss, treatment or unauthorized access, taking into account the state of the technology, the nature of the stored data and the risks to which they are exposed, already come from human action or from the physical or natural environment.


To protect the privacy of the USERS, it is prohibited to send any information regarding their ideology, religion, beliefs, racial origin, health, and sexual life through our forms.


Likewise, we inform you that, under no circumstances will automated individual decisions or profiling be made.